• Explore /
  • Poster
  • / Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.

Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.

Abstract Poster

Authors

null

Diane Damotte

U1138, Centre de Recherche des Cordeliers; Pathology, Hôpital Cochin, Paris, France

Diane Damotte , Yoan Velut , Barbara Burroni , Gary Birsen , Julien Lavergne , Audrey Mansuet-Lupo , Isabelle Cremer , Julien Mazieres , Jacques Cadranel , Gerard Zalcman , Radj Gervais , Gaelle Jeannin , Olivier Molinier , Thomas Egenod , Olivier Carre , Celia Berndt , Alexandra Langlais , Franck Morin , Virginie Westeel , Marie Wislez

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT03030131

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 8022)

DOI

10.1200/JCO.2024.42.16_suppl.8022

Abstract #

8022

Poster Bd #

284

Abstract Disclosures

Similar Posters

First Author: T.R. Jeffry Evans

First Author: Felix Blanc-Durand

First Author: Biagio Ricciuti

First Author: Katherine L. Pogue-Geile